Hospital Universitario Rey Juan Carlos

Mostoles 16 trials 7 recruiting

16 Registered trials

7 Currently recruiting

Organisation

Hospital Universitario Rey Juan Carlos

Location

Mostoles, Spain

Identifier

ORG-100047678

Address

Calle Gladiolo S/n, 28933, Spain

Departments

034033:
1412:Dermatología
Hematología
Hematology
Intensive Medicine
Internal Medicine
Medical Oncology
Neurology
Obstetrics and Gynecology
Oncolgy
Oncology
Radiation Oncology
Urologia

Clinical trials at this site (16)

Search interface

Optimizing Aspirin Use for Preeclampsia Prevention Pending

2025-524646-94-00 Obstetrics – Preeclampsia 11
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Inhaled sedation in the critically ill patient Recruiting

2024-518521-14-00 Critical condition 6 2025-10-17
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontin… Recruiting

2024-514833-39-00 Stress or mixed urinary incontinence in women over 50 y 3 2024-12-16
Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting

2024-511959-18-01 Acute Pulmonary Embolism 5 2024-07-01
Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c… Recruiting

2023-505024-62-01 Oligometastatic patients with castration-resistant pro 4 2024-05-16
VACCINE EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE CAP USING A TEST-NEGATIVE DESIGN Recruiting

2023-507293-40-00 VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRE 6 2024-04-11
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy,… Ended

2023-505739-12-01 Chronic Inducible Urticaria (CINDU) 5 2024-09-30
Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended

2023-503403-28-00 treatment naïve patients with HR+/HER2-negative high-ri 4 2022-11-25
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex… Ended

2023-506877-37-00 Relapsed/Refractory Multiple Myeloma 5 2020-09-28
Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended

2023-510537-28-00 Multiple Myeloma 5 2020-05-15
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Ended

2024-511292-15-00 Advance Radioactive-Iodine Refractory Differentiated Th 4 2023-05-25
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18